Neuromyelitis optica IgG causes placental inflammation and fetal death.

Neuromyelitis optica IgG causes placental inflammation and fetal death.

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS and affects women of childbearing age. Most patients with NMO have circulating Abs, termed NMO-IgG, against the astrocytic water channel protein aquaporin-4. In the CNS, NMO-IgG causes complement-mediated astrocyte damage...

Bibliografiset tiedot
Päätekijät:	Saadoun, S, Waters, P, Leite, M, Bennett, J, Vincent, A, Papadopoulos, M
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2013

Samankaltaisia teoksia

Neuromyelitis optica IgG causes placental inflammation and fetal death in mice
Tekijä: Saadoun, S, et al.
Julkaistu: (2013)

Effect of IgG from seronegative and seropositive neuromyelitis optica patients on mouse brain
Tekijä: Saadoun, S, et al.
Julkaistu: (2013)

NMO-IgG in the diagnosis of neuromyelitis optica.
Tekijä: Jarius, S, et al.
Julkaistu: (2007)

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
Tekijä: Saadoun, S, et al.
Julkaistu: (2010)

Devic's neuromyelitis optica: Prognostic implications of NMO IgG status in Turkish patients
Tekijä: Akman-Demir, G, et al.
Julkaistu: (2008)

Seroprevalence of Neuromyelitis Optica-IgG of Childhood Compared to Adults
Tekijä: J Gordon Millichap
Julkaistu: (2008-02-01)

Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica.
Tekijä: Kim, S, et al.
Julkaistu: (2011)

IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica
Tekijä: Jacob, S, et al.
Julkaistu: (2008)

An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica
Tekijä: Littleton, E, et al.
Julkaistu: (2006)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
Tekijä: Narayanan Unni, et al.
Julkaistu: (2013-01-01)

Revised diagnostic criteria for neuromyelitis optica--incorporation of NMO-IgG status.
Tekijä: Jarius, S, et al.
Julkaistu: (2007)

Cytotoxic edema in a patient with neuromyelitis optica: This may be suggestive of various pathogenic roles of NMO-IgG
Tekijä: Min, J, et al.
Julkaistu: (2010)

IgG subclasses of disease-specific antibodies and complement activation in vitro in myasthenia gravis and neuromyelitis optica
Tekijä: Jacob, S, et al.
Julkaistu: (2007)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
Tekijä: Jarius, S, et al.
Julkaistu: (2007)

Reduced serum IgG galactosylation is associated with increased inflammation during relapses of neuromyelitis optica spectrum disorders
Tekijä: Shiyu Gao, et al.
Julkaistu: (2024-03-01)

Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain
Tekijä: Saadoun, S, et al.
Julkaistu: (2012)

Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain.
Tekijä: Saadoun, S, et al.
Julkaistu: (2012)

Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica Soroprevalência do anticorpo NMO-IgG em pacientes brasileiros com neuromielite óptica
Tekijä: Tarso Adoni, et al.
Julkaistu: (2008-06-01)

Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder
Tekijä: Lukmanee Tradtrantip, et al.
Julkaistu: (2021-11-01)

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
Tekijä: Tianjiao Duan, et al.
Julkaistu: (2018-10-01)

Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder
Tekijä: Eun Bin Cho, et al.
Julkaistu: (2024-03-01)

Risk factors and prognosis of orotracheal intubation in aquaporin-4-IgG neuromyelitis optica spectrum disorder attacks
Tekijä: Edouard Januel, et al.
Julkaistu: (2024-01-01)

Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica
Tekijä: Nisa Vorasoot, et al.
Julkaistu: (2024-11-01)

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica
Tekijä: Lukmanee Tradtrantip, et al.
Julkaistu: (2019-03-01)

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
Tekijä: Oliver Schmetzer, et al.
Julkaistu: (2021-03-01)

Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis
Tekijä: Li Xu, et al.

Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder
Tekijä: Zhichao Li, et al.
Julkaistu: (2023-01-01)

Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders
Tekijä: Koon Ho Chan, et al.
Julkaistu: (2018-01-01)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
Tekijä: Waters, P, et al.
Julkaistu: (2015)

NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro
Tekijä: Jarius, S, et al.
Julkaistu: (2007)

Neutrophil protease inhibition reduces NMO-IgG-induced damage in mouse brain
Tekijä: Papadopoulos, M, et al.
Julkaistu: (2011)

Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity
Tekijä: Tianjiao Duan, et al.
Julkaistu: (2019-07-01)

Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability.
Tekijä: Alvaro Cobo-Calvo, et al.
Julkaistu: (2020-01-01)

Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.
Tekijä: Jacob, A, et al.
Julkaistu: (2012)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
Tekijä: Viegas, S, et al.
Julkaistu: (2009)

T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement.
Tekijä: Saadoun, S, et al.
Julkaistu: (2011)

Complement activation in patients with neuromyelitis optica
Tekijä: Nytrova, P, et al.
Julkaistu: (2014)

Complement activation in patients with neuromyelitis optica.
Tekijä: Nytrova, P, et al.
Julkaistu: (2014)

IgG Placental Transfer in Healthy and Pathological Pregnancies
Tekijä: Patricia Palmeira, et al.
Julkaistu: (2012-01-01)

Use of mitoxantrone in neuromyelitis optica.
Tekijä: Kitley, J, et al.
Julkaistu: (2011)